- Solutions
Applikate Solutions
What they're saying
"Applikate has an excellent team with a breakthrough technology that has the potential to change the world of histopathology." - Company
Company
What they're saying
"Applikate’s new technologies will positively disrupt an entire branch of medical science and business." - Contact
Contact
What they're saying
"Applikate has developed a unique approach to pathology that accelerates diagnosis, eliminates costs, and negates the need for wax embedding and toxic agents. I believe the company will disrupt the field of histology."
Faster processes. Same-day assessments. Expert consultations from anywhere.
Tissue preparation for microscopic examination is time-consuming and technique-dependent, resulting in variable quality which complicates diagnostic interpretation by physicians and digital analysis systems.
Physical slides also reduce the ability of medical specialists to collectively review the patient’s condition and collaboratively determine the best treatment plan.
our focus
About Applikate
Applikate Technologies is a hardware and software company that has developed the first automated histology platform with integrated digital imaging. Our patented technology stains and images whole samples without the need for physical slicing. The platform automates the pathology workflow, cuts processing time, lowers labor and materials costs, improves image quality, and reduces the risk of misdiagnosis.
Our Mission
Applikate's mission is to modernize pathology with technology that significantly reduces hospital costs, improves medical diagnosis, and enables a faster clinical response to patients.
Our Vision
Applikate envisions a world without the need for physical slides and prohibitively expensive histology equipment and storage.
Our Mission
Applikate's mission is to modernize pathology with technology that significantly reduces hospital costs, improves medical diagnosis, and enables a faster clinical response to patients.
Our Vision
Applikate envisions a world without the need for physical slides and prohibitively expensive histology equipment and storage.
The Applikate Advantage
From over 20 manual steps reduced to 3 simple steps.
The time and cost of producing physical slides constrains the number of slides per patient that a pathologist reviews, limiting the diagnostic information at their disposal.
Immediate visualization of multiple tissue layers
Globally accessible images from software that navigates multiple tissue levels for improved diagnosis and analysis.
Elimination of physical slides
Legacy technologies compensate for physical slide limitations by layering more equipment and steps on an archaic process.
High resolution multiphoton microscopy at depth
The fastest high-resolution multiphoton microscope in the world, sub-micron resolution at depth.
-
Our Patented Pathology Platform:
Obsoletes wax, microtomes, & microscopes
By imaging intact, un-embedded tissue biopsies, Applikate's patented pathology technology enables expert human diagnosis within 3 hours of receipt of tissue.
-
Our Increased THROUGHPUT & LOWER COST:
Eliminates tissue slices, slides, & overtime
With our technology, hospital pathology departments reduce processing time from 16 hours to less than 3 hours.
-
OUR DISRUPTIVE, SCALABLE TECHNOLOGY:
Enhances tissue samples, labs, & hospitals
Applikate introduces a modern, direct-to-digital pathology platform that eliminates physical slides, cuts histotech time by 80 percent, and improves diagnosis.
Our Timeline
Important Milestones
Since 2013, Applikate has been revolutionizing pathology, reducing medical errors, and lowering cost.
2013
Applikate Founded
Torres and Levene establish Applikate Technologies, LLC in New Haven, CT after publishing an innovative approach to clinical histology using unique chemical combinations and advanced microscopy.
2014
First Grant
National Cancer Institute awards Applikate’s first NIH SBIR grant.
2014
Stackstreamer Software
Initial version of Applikate’s Stackstreamer software demonstrates practical, web-based, image navigation of arbitrarily large three-dimensional digital histology data sets.
2015
Proprietary Tissue Processing
Applikate develops proprietary tissue processing method for multiphoton imaging with cost, speed, and quality features enabling clinical use.
2015
NIH Award
Applikate receives NIH SBIR award from National Institute of Biomedical Imaging and Bioengineering.
2016
Article Publication
Published article illustrates unique capabilities of CHiMP for assessment of human renal tissue specimens.
2017
First Proprietary System
Applikate builds first advanced proprietary system for high-speed, high-resolution, multiphoton microscopy of clinical specimens.
2017
Follow-On Grant
Applikate receives follow-on NIH/NCI SBIR grant funding to continue CHiMP development.
2018
First Prototype
Applikate builds first prototype of automated tissue processor for CHiMP that requires no human handling.
2018
First Clinical Study
Applikate Technologies and Yale-New Haven Hospital begin first clinical study using Applikate’s CHiMP platform for prostate cancer patients.
2019
Fourth NIH Award
Applikate awarded fourth NIH/NCI SBIR to explore specialized applications of CHiMP.
2019
Applikate In The Media
Various publications and presentations highlight CHiMP’s potential impact in breast cancer, liver disease, kidney disease, and research histology applications.
2019
NIDDK Grant
Applikate receives grant from National Institute of Diabetes and Digestive and Kidney Diseases for development focused on renal pathology.
2020
Key Patents Granted
U.S. Patent Office grants key patents to Applikate covering various aspects of the CHiMP platform.
2020
Applikate Joins CDL
Applikate joins the Creative Destruction Lab (CDL) business incubator.
2020
Prostate Cancer Diagnosis Study
Published prostate cancer diagnostics study demonstrates viability of CHiMP as a primary diagnostic platform with critical advantages.
2021
CDL Showcase
CDL showcases Applikate at its annual Super Session.
2021
Over-Subscribed Seed Round
Applikate closes over-subscribed seed round and becomes Applikate Technologies, Inc.
2022
Second Clinical Validation Round
Applikate begins second phase of clinical validation studies using CHiMP.